Recent Updates
Recently added Catalysts

Apogee Therapeutics, Inc.

APGE
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$135.07
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full APGE financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $35.3952W HIGH $135.09
Volume
5.14 M
Value Traded
102.49 M
Short % Float
7.33%
-0.01%Week
+0.17%1 Month
+62.72%3 Month
+80.24%6 Month
+277.49%5 Year
+277.49%All Time

Cash Data

Unlock APGE cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.40 B
EPS (TTM)
-3.89
P/E Ratio
-
Ent. Value
7.11 B
Total Shares
61.88 M
Float Shares
57.30 M
Insiders
19.21%
Institutions
76.76%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1b data readout
APG279
Moderate-to-severe atopic dermatitis
Phase 1bBiologicsDermatologic System
Unlock every APGE catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

APGE Catalyst Timeline

Dated clinical, regulatory and corporate events for Apogee Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Apogee Therapeutics, Inc.

156Total events
9Upcoming
52Tier-1 (high impact)
2023 to 2029Coverage

Upcoming catalysts 2

T2Runway Guidance Update
Subscribe to view catalyst details
T2Trial Initiation
Subscribe to view catalyst details
zumilokibart

Event history 50

▲AcquiredCorporate
AbbVie completes acquisition of Apogee Therapeutics
source ↗
▲AcquiredCorporate
AbbVie to acquire Apogee for $135.11 per share in cash
source ↗
▲Topline ReadoutAPEXClinical Data
Positive 16-week Phase 2 APEX Part B induction dose optimization results
source ↗
●Quarterly UpdateCorporate
AbbVie reaffirms Q3 2026 adjusted diluted EPS guidance
source ↗
▲AcquiredCorporate
AbbVie to acquire Apogee Therapeutics for $135.11 per share
source ↗
●Quarterly UpdateCorporate
Investor conference call to discuss transaction
source ↗
▲Primary Endpoint MetzumilokibartClinical Data
Phase 2 trial of zumilokibart met primary endpoint with significant skin clearance at 16 weeks
atopic dermatitissource ↗
▲Long Term DatazumilokibartClinical Data
Longer-term data from Phase 2 trial supports quarterly or twice-yearly maintenance dosing
atopic dermatitissource ↗
▲Full ResultsAPG333Clinical Data
Phase 1 data for APG333 showed long half-life and suppression of type 2 inflammatory markers for up to six months
asthmasource ↗
▲Interim AnalysiszumilokibartTrial
Positive interim results from Phase 1b study of zumilokibart in asthma
asthmasource ↗
Unlock the full APGE catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How APGE actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31APG333 (novel, subcutaneous half-life extended monoclonal antibody) Phase 1 data readout Phase 1
Unlock 3 more APGE historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C40 / 100
Pipeline Score
$514M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Apogee Therapeutics, Inc. carries a moderate pipeline score (40/100), with $791M risk-adjusted pipeline value, led by APG777 in Atopic Dermatitis (Phase 2), across $52B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
APG777 Small moleculeNCT07027527Atopic DermatitisPhase 2 ACTIVE NOT_RECRUITING 906Dec 1, 2027
Unlock the APGE pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every APGE program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
zumilokibart moderate-to-severe atopic dermatitisPhase 22026-05-27EASI 75: 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted)Read MoreApogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic DermatitisRead More
Scroll for more · summaries link to the source press release
Unlock every APGE trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock APGE insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Fairmount Funds Management LLCDirectorOption 31,838 330,485 held$17.00 08/07/2026
Unlock the full APGE insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in APGE

Fund % of Portfolio Current MV Shares Owned Activity
VR Adviser, LLC 34.2 % (28.1 %) 1.13 B 8.49 M
Unlock every fund holding APGE
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in APGE
Shares held by hedge funds each quarter, and who bought or sold.

APGE Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock APGE option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live APGE option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock APGE options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How APGE ranks across every disease it competes in

Competitive Position is a premium feature
See how APGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

APGE News

About Apogee Therapeutics, Inc.

San Francisco, CA 261 employees apogeetherapeutics.com
Headquarters1 LETTERMAN DRIVE, SAN FRANCISCO, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next APGE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime